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Background: LOX-1, a lectin-like receptor on endothelial cells, facilitates the uptake of oxidized low-density lipoprotein
(oxLDL). Expression of LOX-1 is involved in the pathobiological effects of oxLDL in endothelial cells, including reactive
oxygen species (ROS) generation, suppression of endothelial nitric oxide synthase (eNOS) activity, and leukocytic
adhesion. Moderate consumption of phenolic-enriched food may have a protective effect against the development of
atherosclerosis via the antioxidant capacity of phenolic compounds at the endothelial level. In this study, we determined
whether ellagic acid, a polyphenolic compound widely distributed in fruits and nuts, protects against oxLDL-induced
endothelial dysfunction by modulating the LOX-1-mediated signaling pathway.
Methods: Human umbilical vein endothelial cells (HUVECs) were pretreated with ellagic acid at doses of 5, 10, 15, and
20 M for 2 hours and then incubated with oxLDL (150 g/mL) for an additional 24 hours.
Results: LOX-1 protein expression was markedly lower after exposure to oxLDL in HUVECs pretreated with ellagic acid
or diphenyleneiodonium, a well-known inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase,
than in HUVECs exposed to oxLDL alone, suggesting that ellagic acid deactivates NADPH oxidase. We also found that
oxLDL activated the membrane assembly of p47phox, Rac1, gp91 and p22phox, and the subsequent induction of ROS
generation; however, ROS generation was markedly suppressed in cells pretreated with ellagic acid or anti-LOX-1
monoclonal antibody. In addition, oxLDL down-regulated eNOS and up-regulated inducible NO synthase (iNOS),
thereby augmenting the formation of NO and protein nitrosylation. Furthermore, oxLDL induced the phosphorylation
of p38 mitogen-activated protein kinase, activated the NF-B-mediated inflammatory signaling molecules interleukin-
(IL) 6 and IL-8 and the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and
E-selectin, and stimulated the adherence of THP-1 (a human acute monocytic leukemia cell line) to HUVECs.
Pretreatment with ellagic acid, however, exerted significant cytoprotective effects in all events.
Conclusion: Findings from this study may provide insight into a possible molecular mechanism by which ellagic acid
inhibits LOX-1-induced endothelial dysfunction. Our data indicate that ellagic acid exerts its protective effects by
inhibiting NADPH oxidase-induced overproduction of superoxide, suppressing the release of NO by down-regulating
iNOS, enhancing cellular antioxidant defenses, and attenuating oxLDL-induced LOX-1 up-regulation and eNOS
down-regulation. (J Vasc Surg 2010;52:1290-300.)
Clinical Relevance: Increased oxidative stress is an important factor contributing to the development of atherosclerotic
lesions. This study underscores the potential clinical benefits and application of ellagic acid in prevention of oxLDL-associated
atherogenic diseases.
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Volume 52, Number 5 Lee et al 1291Atherosclerosis is a chronic inflammatory process. The
initiation of atherosclerotic lesion formation is caused by
sublethal changes in endothelial function, a process re-
ferred to as endothelial activation or dysfunction. Oxidized
low-density lipoprotein (oxLDL) impairs endothelial func-
tion, giving rise to reactive oxygen species (ROS) genera-
tion, and reduced nitric oxide (NO) production. Adhesion
molecules are then activated, which in turn mediates leu-
kocyte recruitment and adherence to the endothelium.1
LOX-1 is a lectin-like receptor for oxLDL in endothe-
lial cells, smooth muscle cells, and macrophages, the three
most important cells involved in the development of ath-
erosclerosis.2 This receptor has been shown to be activated
by shear stress, endothelin, angiotensin II, and oxLDL in
atherosclreotic lesions in humans and experimental animal
models. Specifically, uptake of oxLDL into the endothe-
lium is mediated through interaction with the LOX-1
receptor. It is this interaction that mediates most of the
toxic effects of oxLDL, including the release of inflamma-
tory cytokines and the enhanced expression of adhesion
molecules and pro-apoptotic proteins. The binding of
oxLDL to LOX-1 activates nicotinamide adenine dinucle-
otide phosphate (NADPH) oxidase on the cell membrane,
which results in the quick increase of intracellular ROS,
including superoxide (O2
) and hydrogen peroxide
(H2O2). Increased O2
 not only reacts with intracellular
NO, resulting in a decrease in intracellular NO, but also
up-regulates LOX-1 expression, thereby contributing to
further ROS generation.3 ROS derived from NADPH
oxidase is strongly associated with atherosclerosis,4 and
oxLDL-induced endothelial dysfuction is prevented by
radical-scavenging agents.3 Clinically, however, free radical
scavengers such as recombinant human superoxide dis-
mutase (SOD) and catalase enzyme have been shown to
have limited effects, perhaps due to their short half-life and
to their very low penetration in vascular tissues.5
There is increasing evidence regarding the link between
the dietary intake of fruits and vegetables and the lower
incidence of cardiovascular diseases. These beneficial effects
are now suggested to be due to the antioxidant activity of
constituent phenolic phytochemicals.6 Phenolic phyto-
chemicals possess phenolic rings and hydroxyl substituents
with the ability to quench free radicals and prevent cellular
damage, and, therefore, function as effective antioxidants.
Polyphenolic compounds affect the development of ath-
erosclerosis not only through antioxidant properties but
also by modulation of serum lipids, thereby influencing the
immune and inflammatory processes associated with the
development of atherogenic diseases.
Ellagic acid is a natural polyphenolic compoundpresent as
ellagitannins in fruits and fruit juices, including grape juice
(10.2 mg/100 g), grape wine (5.6 mg/100 g), blueberries
(0.9 mg/100 g), blackberries (42.4 mL/100 g), raspberries
(17.9 mg/100 g), and strawberries (19.8 mg/100 g).7 El-
lagic acid is released by the metabolism of ellagitannins by the
microflora in the gut.8 Several biological activities of ellagic
acid have been investigated, including anti-oxidation and in-
hibition of lipid peroxidation,9 anti-inflammation,10 anti-pro-liferation and anti-angiogenesis,11 and anti-carcinogenesis and
chemoprevention.12 Ellagic acid effectively lowers the lev-
els of plasma lipids, reduces oxidative stress, and inhibits
apoptosis in hyperlipidemic rabbits,13 as well as scavenges
oxygen and hydroxyl radicals, and inhibits lipid peroxida-
tion and 8-OhdG formation in vitro and in vivo.14 Previous
studies have shown that ellagic acid inhibits oxLDL-induced
aortic smooth muscle cell proliferation,15 inhibits cytokine-
induced ROS generation and expression of adhesion mole-
cules,16,17 and prevents oxLDL-induced apoptosis18 in endo-
thelial cells. The underlying mechanisms, however, are still
largely unclear. Therefore, in this study, we used human
umbilical vein endothelial cells (HUVECs) to test the hypoth-
esis that ellagic acid protects against oxLDL-induced endo-
thelial dysfunction by modulating the LOX-1-mediated sig-
naling pathway. In so doing, we explored the effects of ellagic
acid on oxLDL-induced ROS generation, antioxidant en-
zyme expression, NADPHoxidase activation, LOX-1 protein
expression, andNF-B-relative downstream inflammatory re-
sponses.
MATERIALS AND METHODS
Cell cultures. HUVECs were isolated from human
umbilical cords with collagenase and used at passages
2-3.19 After dissociation, the cells were collected and cul-
tured on gelatin-coated culture dishes in M199 with low
serum growth supplement, 100 IU/mL penicillin, and 0.1
mg/mL streptomycin. Subcultures were performed with
trypsin-ethylenediaminetetraacetic acid (EDTA). Media
were refreshed every second day. The identity of umbilical
vein endothelial cells was confirmed by their cobblestone
morphology and strong positive immunoreactivity to von
Willebrand factor. THP-1, a human monocytic leukemia
cell line, was obtained from ATCC (Rockville, Md) and
cultured in RPMI 1640 medium with 10% fetal bovine
serum at a density of 2 to 5 106 cells/mL, as suggested in
the product specification sheet provided by the vendor.
Lipoprotein separation and oxidation. Native LDL
was isolated from fresh normolipidemic human serum by
the sequential ultracentrifugation method and then oxida-
tively modified.20 LDL (  1.019-1.210 g/mL) in KBr
solutions containing 30 mM EDTA was stored at 4°C in a
sterile, dark environment and used within 3 days. Immedi-
ately before oxidation tests, LDL was separated from
EDTA and from diffusible low molecular mass compounds
by gel filtration on PD-10 Sephadex G-25 M gel (Pharma-
cia, St. Quentin, France) in 0.01M phosphate-buffered
saline (PBS; 136.9 mM NaCl, 2.68 mM KCl, 4 mM
Na2HPO4, and 1.76 mM KH2PO4, pH 7.4). CuSO4-
oxidized LDL (1 mg protein/mL) was prepared by expos-
ing LDL to 10 M CuSO4 for 16 hours at 37°C. Protein
was measured by the Bradford method.21
Measurement of ROS production. The effect of el-
lagic acid on ROS production in HUVECs was determined
by a fluorometric assay using dihydroethidium (DHE,
Molecular Probes, Eugene,Ore) as a probe for the presence of
superoxide. After preincubation for 2 hourswith the indicated
concentrations of ellagic acid, HUVECs were incubated with
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hours. The fluorescence intensity was measured at 540 nm
excitation and 590 nm emission (before and after exposure to
oxLDL) using a fluorescence microplate reader (Labsystems,
San Jose, Calif). The percentage increase in fluorescence per
well was calculated by the formula [(Ft2 Ft0)/Ft0] 100,
where Ft2 is the fluorescence at 2 hours of oxLDL exposure
and Ft0 is the fluorescence at 0 min of oxLDL exposure.
OxLDL-induced superoxide formation, which occurs largely
through activation of NADPH oxidase, but also through
uncoupling of endothelial NO synthase, xanthine oxidase,
peroxisomes, and through direct superoxide release, leads to
endothelial dysfunction. In this regard, diphenyleneiodonium
(DPI), a potent inhibitor of flavin-containing oxidase, has
frequently been used to inhibit ROS production mediated by
various flavoenzymes, including NADPH oxidase, quinine
oxidoreductase, cytochrome P450 reductase, and nitric oxide
synthase.22 To evaluate the role of NADPH oxidase and
LOX-1 in oxLDL-induced ROS generation, cells were prein-
cubated with DPI (5 M) or anti-LOX-1 mAb (40 g/mL)
for 2 hours before exposure to oxLDL.
Nitrite (NO2
) accumulation. NO2
 accumulation
was used as an indicator of NO production in the medium
andwas assayed byGries reagent.23 Briefly, 100L of Gries
reagent (1% sulfanilamide, 0.1% naphthylethylene diamine
dihydrochloride, and 2.5% H3PO4; Sigma, St. Louis, Mo)
was added to 100 L of each supernatant in triplicate wells
of 96-well plates. The plates were read in a microplate
reader (Molecular Devices, Palo Alto, Calif) at 550 nm
against a standard curve of NaNO2 in culture medium.
Immunoblotting. To determine whether ellagic acid
could attenuate the expression of oxLDL-induced ROS-
regulating proteins, HUVECs were grown to confluence,
pretreated with ellagic acid for 2 hours, and then stimulated
with oxLDL for indicated time periods. After treatment,
cytosolic/membrane protein fractions of cells were extracted
with a Mem-PER kit, and cytosolic/nuclear protein fractions
of cells were extracted with a Cytoplasmic Extraction kit
according to the manufacturer’s instructions (Pierce, Rock-
ford, Ill). Cytosolic SOD-1, SOD-2, nitrotyrosine, eNOS,
iNOS, and IB membrane-bound gp91, p22phox, p47phox,
and Rac-1, and nuclear NF-Bp65 were determined by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis and
immunoblot assay. The blots were incubated with blocking
buffer (1x PBS and 5% nonfat dry milk) for 1 hour at room
temperature and then probed with primary antibodies (1:
1000 dilutions) overnight at 4°C, followed by incubation
with horseradish peroxidase-conjugated secondary antibody
(1:5000) for 1 hour. To control equal loading of total
protein in all lanes, blots were stained with mouse anti
-actin antibody (1:50,000 dilution) for cytosolic frac-
tions, mouse anti-flotillin-1 (1:1000) for plasmamembrane
fractions, and anti-proliferating cell nuclear antigen (1:
1000) for nuclear fractions. The bound immunoproteins
were detected by an enhanced chemiluminescent assay
(ECL; Amersham, Berkshire, UK). The intensities were
quantified by densitometric analysis (Digital Protein DNA
Imagineware, Huntington Station, NY).Assay for ET-1, interleukin-(IL) 6 and IL-8 sec-
retion. Endothelial dysfunction caused by oxLDL has
been attributed to reduced NO bioavailability and en-
hanced ET-1/cytokine release.24 To determine the effects
of ellagic acid on oxLDL-induced ET-1 and IL-8 secretion,
HUVECs were seeded in 24-well plates at 0.5  105 cells.
After 2 days, cells were pretreated with the indicated con-
centrations of ellagic acid for 2 hours followed by treatment
with oxLDL (150 g/mL) for 24 hours. At the end of the
oxLDL incubation period, cell supernatants were removed
and assayed for ET-1 and IL-8 concentration using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, Minn). Data were expressed in
ng/mL of duplicate samples.
Adhesion assay. HUVECs at a density of 1  105
cells/mL were cultured in 96-well flat-bottom plates (0.1
mL/well) for 1 to2days.HUVECswere thenpretreatedwith
the indicated concentrations of ellagic acid for 2 hours, fol-
lowed by stimulation with oxLDL (150 g/mL) for 24
hours. Medium was removed and 0.1 mL/well of THP-1
cells (prelabeled with BCECF-AM 4 M for 30 minutes in
RPMI1640medium at 1106 cell/mLdensity) were added
toHUVECs. Cells were allowed to adhere at 37°C for 1 hour
in a 5% CO2 incubator. Non-adherent cells were gently aspi-
rated. Plates were washed three times with M199. The num-
ber of adherent cells was estimated by microscopic examina-
Fig 1. Inhibitory effect of ellagic acid on oxidized low-density
lipoprotein (oxLDL)-induced endothelial LOX-1 protein expres-
sion. Human umbilical vein endothelial cells (HUVECs) were
pretreated with ellagic acid (5-20 M) or DPI (5 M) for 2 hours
followed by exposure to oxLDL (150 g/mL) for a further
24-hour period. At the end of the incubation period, cells were lysed
and proteins were analyzed by Western blot. Protein levels of LOX-1
were normalized to the level of -actin. Data illustrated on the graph
bars represent the mean	 SEM of three different experiments. *P

.05 compared with oxLDL-stimulated HUVECs.tion and then the cells were lysed with 0.1 mL 0.25% Triton
stimu
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excitation and 538 nm emission using a fluorescence micro-
plate reader (Labsystems). The results of monocytes adhesion
assays are reported as the fluorescence intensity per well of
adherent THP-1 cells.
Adhesion molecule expression. To determine whether
ellagic acid could modify oxLDL-induced adhesion mole-
cule expression, HUVECs at a density of 1 105 cells/mL
were grown to confluence and pretreated with 20 M
ellagic acid for 2 hours and stimulated with oxLDL (150
g/mL) for 24 hours. At the end of stimulation, HUVECs
were harvested and incubated with FITC-conjugated anti-
intercellular adhesion molecule (ICAM)-1, anti-vascular
cell adhesion molecule-1 (VCAM-1), and anti-E-selectin
for 45 minutes at room temperature. After the cells had
been washed three times, immunofluorescence intensity
was analyzed using flow cytometry with a Becton Dickin-
son FACScan (Mountain View, Calif).
Statistical analyses. Results are expressed as mean 	
SEM. Differences between the groups were analyzed using
one-way analysis of variance followed by the Student’s t test. A
(A )
control oxLDL oxLDL+ellagic acid
(B)
R
O
S
(%
of
in
cr
ea
se
)
0
100
200
300
400
500
600
oxLDL (150 µg/ml) - + + + + + + +
ellagic acid (µM) 0 0 5 10 15 20 0 0
mAb anti-LOX-1 - - - - - + + -
DPI (5 µM) - - - - - - - +
*
**
*
*
*
Fig 2. Inhibitory effects of ellagic acid on oxidized low
(ROS) production in human umbilical vein endothelial
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ellagic acid (right). (B) Fluorescence intensity of cells was
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0.05 was considered statistically significant.RESULTS
Effect of ellagic acid on oxLDL-induced protein
expression of LOX-1. First, we found that the endothelial
viability was not affected by ellagic acid up to 50 M. The
ED50 (the half-maximal effective concentration) of ellagic
acid was calculated to be 6.3 M after exposure to 150
g/mL oxLDL for 24 hours (data not shown). Therefore,
150 g/mL of oxLDL and 5 to 20 M of ellagic acid were
used in the following experiments. Incubation of HUVECs
with oxLDL enhanced LOX-1 protein expression. Pretreat-
ment of HUVECs with ellagic acid for 2 hours at concentra-
tions above 5 M, followed by exposure to oxLDL for 24
hours resulted in suppression of LOX-1 protein expression. In
addition, pretreatment with DPI, an inhibitor of ROS pro-
duction, markedly inhibited oxLDL-induced LOX-1 up-reg-
ulation, strongly suggesting that ROS plays a critical role in
the increased protein expression of LOX-1 (Fig 1).
Effects of ellagic acid on oxLDL-induced ROS
generation. Pretreatment of HUVECs with ellagic acid
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 .05; Fig 2A, 2B). In
addition, oxLDL-induced ROS was abolished by pretreat-
ment with monoclonal antibody of LOX-1 (mAb anti-
LOX-1) or DPI (Fig 2B), suggesting that ROS generation,
one of the earliest signals after oxLDL exposure, was largely
dependent on the binding of oxLDL to LOX-1 and subse-
quent activation of NADPH oxidase.
Intracellular ROS levels are regulated by the balance
between ROS generation and antioxidant enzymes. ROS
are able to inactivate antioxidative enzymes, leading to
oxidative stress. We next turned our attention to the ex-
pression of SOD isoforms in endothelial cells in response to
oxLDL. Our results showed that Cu, Zn-SOD (SOD-1),
but not Mn-SOD (SOD-2), expression was diminished
after treatment with oxLDL for 24 hours; however, SOD-1
was expressed normally after pretreatment with ellagic acid
at concentrations above 15 M (Fig 2, C and D).
Effects of ellagic acid on oxLDL-induced mem-
brane assembly of NADPHoxidase complex. TheNOX
Fig 3. Ellagic acid attenuated the level of NADPH oxi
cells (HUVECs) were pretreated for 2 hours with the ind
with oxidized low-density lipoprotein (oxLDL) (150 g
membrane and cytosolic proteins is described in the Mat
membrane protein were normalized to the levels of -ac
and summary data showed that ellagic acid protected ag
plasma membrane, and gp91 as well as p22phox expressi
experiments. *P 
 .05 vs oxLDL treatment.family of NADPH oxidases is a major source of ROS inendothelial cells.25 This enzyme complex is composed of two
membrane components, Nox2 (also called gp91phox) and
p22phox, and three cytoplasmic components, p47phox,
p67phox, and the small GTPase rac-1. The process by which
theNADPHoxidase enzyme complex is activated beginswith
the phosphorylation of p47phox, which causes the transloca-
tion of the p47phox/p67phox complex to the plasma mem-
brane where p47phox interacts with p22phox and p67phox acts
as the NOX activator through direct protein-protein interac-
tion.26 We, therefore, measured the effects of ellagic acid on
NADPH oxidase activation after exposure to oxLDL. Mem-
brane translocation assay showed that the levels of p47phox
and Rac-1 in membrane fractions of HUVECs were three- to
four-fold higher in cells treatedwith oxLDL for 1 hour than in
untreated cells (Fig 3A-C). In addition, we found that the
protein levels of gp91 and p22phox were increased significantly
in HUVECs exposed to oxLDL for 24 hours. However,
pretreatment of oxLDL-exposed cells with ellagic acid led to a
dose-dependent reduction in gp91 and p22phox protein ex-
membrane assembly. Human umbilical vein endothelial
d concentrations of ellagic acid followed by stimulation
) for 1 hour (A-C) or 24 hours (D-F). Preparation of
nd Methods section. The levels of cytosolic protein and
d flotillin-1, respectively. Representative Western blots
oxLDL-induced p47phox and Rac-1 translocation to the
he values represent means 	 SEM from three separatedase
icate
/mL
erial a
tin an
ainst
on. Tpression (5-20 M, all P
 .05; Fig 3D-F).
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protein expression and enhanced ET-1. Nitric oxide
(NO) is produced in endothelial cells by a constitutively
expressed enzyme known as eNOS. Considerable evi-
dence indicates that oxLDL-induced endothelial dys-
function is associated with down-regulation of eNOS and
up-regulation of iNOS. ROS, especially superoxide, gener-
ated by oxLDLdirectly, reacts withNO to formperoxynitrite,
a stable molecule that is toxic to endothelial cells. We, there-
fore, determined the effects of ellagic acid on protein expres-
sion of eNOS and iNOS as well as NO content and formation
of nitrotyrosine, a stable final metabolite of peroxynitrate that
can serve as a fingerprint for peroxynitrite-mediated damage
of cellular proteins after exposure to oxLDL. As shown in Fig
4, oxLDL-diminished eNOS and enhanced iNOS protein
expression levels returned to levels close to those seen in
control cells whenHUVECs were treated with 20 Mellagic
acid prior to stimulation with oxLDL. Furthermore, the ox-
LDL-enhanced NO release and nitrosylation of tyrosine resi-
dues were suppressed in HUVECs pretreated with ellagic
Fig 4. Ellagic acid ameliorated the oxidized low-de
regulated iNOS protein expression (A-C), oxLDL-enhan
In addition, ellagic acid attenuated the oxLDL-enhance
cells (HUVECs) were pretreated for 2 hours with the ind
with oxLDL (150 g/mL) for 24 hours. At the end of t
protein (normalized to the levels of -actin) were determ
Gries reagent; ET-1 secretion was measured by ELISA
experiments. *P 
 .05 vs oxLDL treatment.acid.It has been speculated that reduced NO release/bioavail-
ability and enhanced release of endothelin-1 (ET-1) may
contribute to oxLDL-induced endothelial dysfunction and
the development of atherosclerosis.27 We found that the
oxLDL-enhanced ET-1 secretion that was observed in
HUVECs after 24 hours of incubation with oxLDL was
abolished in HUVECs pretreated with ellagic acid (Fig 4G).
Ellagic acid inhibited NF-kB activation via mod-
ulation of p38MAPK. It has been shown that oxLDL-
induced ROS activates p38MAPK, which causes the
activation and nuclear translocation of NF-B and the
subsequent regulation of pro-inflammatory gene expres-
sion.28 We, therefore, determined whether the effects of
ellagic acid are associated with the p38MAPK-NF-B
signaling pathway. Our data showed that oxLDL had no
effect on the level of p38MAPK expression but that it
markedly increased the level of phosphorylation of
p38MAPK. In parallel experiments, HUVECs pretreated
with ellagic acid showed very little p38MAPK phosphory-
lation and normal protein levels of that mitogen-activated
lipoprotein (oxLDL)-down-regulated eNOS and up-
O release (D), and nitration of tyrosine residues (E, F).
retion of ET-1 (G). Human umbilical vein endothelial
d concentrations of ellagic acid followed by stimulation
ubation period, level of eNOS, iNOS, and nitrotyrosine
by immunoblotting; content of NO was assayed using
e values represent means 	 SEM from three separatensity
ced N
d sec
icate
he inc
ined
. Thprotein kinase p38MAPK (Fig 5). NF-B is a family of
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ly.29 Its activation requires the dissociation of inhibitor
factor, IB, and subsequent nuclear translocation,
where NF-B presents as a primary p65/p50 het-
erodimer and binds directly to its cognate DNA se-
quence.30 As shown in Fig 6, after exposure to oxLDL,
IB was degraded, thereby causing nuclear transloca-
tion of NF-Bp65. In contrast, in cells pretreated with
various concentrations of ellagic acid or SB203580, a
specific inhibitor of p38MAPK, NF-B activation was
markedly inhibited (all P 
 .05).
Ellagic acid inhibited NF-kB activated inflamma-
tory response. Levels of inflammatory cytokines IL-6 and
IL-8 were significantly higher in HUVECs that had been
incubated for 24 hours with oxLDL at 150 g/mL than in
untreated control cells; however, ellagic acid significantly
inhibited theseNF-B-mediated inflammatory responses in
a dose-dependent manner (all P 
 .05; Fig 7, A and B).
Flow cytometry revealed that the induction of adhesion
molecules ICAM-1, VCAM-1, and E-selectin expression
were attenuated by 20Mellagic acid (all P
 .05; Fig 7C).
To test the effect of ellagic acid on monocyte adhesion to
HUVECs, confluent monolayers of HUVECs were pre-
treated with various concentrations of ellagic acid for 2
hours and then stimulated with oxLDL (150 g/mL) for
Fig 5. Ellagic acid inhibits oxidized low-density lipoprotein
(oxLDL)-induced p38MAPK protein phosphorylation (p-
p38MAPK). Human umbilical vein endothelial cells (HUVECs)
were pretreated for 2 hours with the indicated concentrations of
ellagic acid followed by stimulation with oxLDL (150 g/mL) for
1 hour. Expression of p38MAPKwas analyzed byWestern blotting
and quantified by densitometry. Treatment with 10 M
SB203580, a specific inhibitor of p38 MAPK, suppressed the
oxLDL-induced phosphorylation of the p38MAPK protein. The
values represent means 	 SEM from three separate experiments.
*P 
 .05 vs oxLDL treatment.24 hours, followed by incubation with THP-1 cells for 1hour at 37°C. As shown in Fig 7D and E, oxLDL stimu-
lated the adherence of THP-1 cells to HUVECs; however,
ellagic acid treatment inhibited this adhesion in a dose-
dependent manner (5-20 M; all P 
 .05).
DISCUSSION
The present study is, to our knowledge, the first report
to show the effects of ellagic acid on the protein expression
of LOX-1 in oxLDL-evoked endothelial dysfunction. We
first demonstrated that ellagic acid decreased the expression
of LOX-1 in HUVECs that had been exposed to oxLDL.
Second, we showed that ellagic acid inhibited superoxide
Fig 6. Effects of ellagic acid on oxidized low-density lipoprotein
(oxLDL)-induced NF-B activation. Human umbilical vein endo-
thelial cells (HUVECs) were pretreated for 2 hours with the
indicated concentrations of ellagic acid followed by stimulation
with oxLDL (150g/mL) for 1 hour. Preparation of cytosolic and
nuclear proteins is described in the Material and Methods section.
The expression levels of the indicated proteins were analyzed by
Western blotting and quantified by densitometry (A). The levels of
cytosolic protein and nuclear protein were normalized to the levels
of -actin and proliferating cell nuclear antigen, respectively
(B, C). The values represent means 	 SEM from three separate
experiments. *P 
 .05 vs oxLDL treatment.generation, one of the earliest signals in oxLDL stimula-
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pathway and the generation of ROS. Because regulation of
LOX-1 involves NF-B, inhibition of LOX-1 may result in
a reduction in the oxidative stress-dependent activation of
NF-B.28 Our finding that ellagic acid concomitantly de-
creases ROS production, NF-B activation, and LOX-1
protein expression supports this possibility.
Increasing evidence indicates that ROS derived from
Fig 7. Effects of ellagic acid on oxidized low-density lip
expression of adhesionmolecules, and adhesiveness of TH
(HUVECs). Cells were incubated with indicated conce
ox-LDL for an additional 24 hours. ELISA measuremen
treated with oxLDL in the absence or presence of in
incubated with oxLDL (150 g/mL) in the absence (lig
hours. The histograms of cell surface expression of I
cytometry. (D) Representative fields of monocytes adhe
(E) Dose-dependent effect of ellagic acid (5-20 M) o
HUVECs was measured as described in theMaterials and
independent analyses. *P 
 .05 vs. oxLDL treatment.NADPH oxidase act as a potent causal factor that initiatesand accelerates the development of atherosclerosis.31
Hence, compounds that suppress NADPH oxidase activa-
tion may ameliorate those complications. Previous studies
have demonstrated that LOX-1 activation induces oxidative
stress, and oxidative stress, in turn, stimulates LOX-1 expres-
sion, suggesting a positive loop between oxidative stress and
LOX-1 expression.32 LOX-1 activation has also been shown
to activate NADPH oxidase and subsequent redox signals
ein (oxLDL)-induced release of inflammatory cytokines,
monocytic cells to human umbilical vein endothelial cells
ons of ellagic acid for 2 hours and then incubated with
wing IL-6 (A) and IL-8 (B) protein levels in HUVECs
d concentrations of ellagic acid. (C) HUVECs were
ay) or presence (dark gray) of 20 M ellagic acid for 24
-1, VCAM-1, and E-selectin were generated by flow
o HUVECs with representative treatments as indicated.
DL (150 g/mL)-induced adhesiveness of THP-1 to
ods section. The values represent mean	 SEM of threeoprot
P-1
ntrati
ts sho
dicate
ht gr
CAM
ring t
n oxL
Methinvolving p38MAPK and NF-B, the latter of which controls
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including cytokines, chemokines, inflammatory enzymes,
and adhesion molecules in endothelial cells.33 Cytoplasmic
NF-B is activated by the cleavage of IB from the p50-65
heterodimer, which is then translocated to the nucleus.
Cleavage of IB requires an oxidizingmilieu and appears to be
one of the mechanisms through which ROS activates NF-
B.34 The LOX-1-mediated signaling pathway involves the
bindingof oxLDL toLOX-1,which results in the activationof
the NADPH oxidase subunits p47phox and Rac-1 on the cell
membrane. Activation of those subunits induces a rapid in-
crease in intracellular ROS and the subsequent activation of
NF-B-mediated downstream inflammatory response via
phosphorylation of p38MAPK. In this study, our hypothesis
was that ellagic acid acts as an antiatherogenic agent by block-
ading the LOX-1-mediated signaling pathway (Fig 8).
ROS generated in endothelial cells include superoxide
(·O2), hydrogen peroxide (H2O2), peroxynitrite (·ONOO),
NO, and hydroxyl (·OH) radicals. SOD protects against
superoxide-mediated cytotoxicity by catalyzing ·O2 to
form H2O2. Cellular levels of superoxide are, therefore,
normally low; however, Cu, Zn-SOD (SOD-1), but not
Mn-SOD (SOD-2), is inactivated by H2O2 formed by
dismutation of the superoxide anion. In this study, we
found that ellagic acid significantly reduced superoxide
generation caused by oxLDL, which subsequently amelio-
rated H2O2-attenuated SOD-1 expression (Fig 2C). We
assume that ellagic acid protects against oxLDL-induced
Fig 8. Schematic diagram showing cytoprotective sig
(oxLDL)-induced endothelial dysfunction. As depicted,
initiated by oxLDL-generated reactive oxygen species (R
inhibition or blockade.endothelial dysfunction by inhibiting LOX-1-mediatedROS generation, thereby preserving H2O2-inactivated
SOD-1. However, whether the effect of ellagic acid is solely
due to its antioxidant activity has not been clearly eluci-
dated. Our finding that the membrane assembly of gp91,
p22phox, p47phox, and Rac-1 after oxLDL exposure was
reduced in cells pretreated with ellagic acid suggests that
the beneficial effects of ellagic acid might be due, at least in
part, to suppression of the membrane assembly of the
NADPH oxidase complex (Fig 3).
Endothelial NO synthase (eNOS), a key regulator of
vascular wall homeostasis, produces NO under normal
physiological conditions. In contrast, the level of NO pro-
duced by inducible NO synthase (iNOS) is several orders of
magnitude higher than that produced by eNOS in athero-
sclerotic lesions. In addition, the increase in NADPH oxi-
dase activity leads to eNOS uncoupling, which results in the
generation of superoxide rather than NO. Many studies
have suggested that the interaction of NO with superoxide
leads to peroxynitrite formation. This radical species is
capable of nitrating tyrosine residues on key regulatory
enzymes that are required for vascular tone.35Our data that
nitrite formation was largely parallel to the expression level
of iNOS (Fig 4,A andC) suggest that generation of NO as
a precursor of nitrite in oxLDL-treated cells is due mainly
to iNOS. However, pretreatment of HUVECs with ellagic
acid suppressed the oxLDL-induced up-reguation of
iNOS, thereby leading to a reduction in NO production
g of ellagic acid in oxidized low-density lipoprotein
ic acid inhibits the LOX-1-mediated signaling cascades
The¡ indicates activation or induction, and; indicatesnalin
ellag
OS).(Fig 4D) and protein nitrosylation (Fig 4, E and F).
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endothelin-1 (ET-1) by oxLDL has been proposed to lead
to an increase in oxidative stress, which would serve as a
critical toxic mechanism for oxLDL in endothelial cells and
is partially reversed by antioxidant treatment.24 OxLDL
antagonizes the vasodilatory effect of NO, and ROS and
NO antagonize each other at the level of intracellular
signaling; for example, NO released from eNOS inhibits
cleavage of IB and NF-B activation, which is enhanced
by ROS.36 Consistent with a previous study that revealed
that ellagic acid inhibits cytokine-induced adhesion mole-
cule expression,17 our data showed that the antiathrogenic
effects of ellagic acid are due, at least in part, to the
inhibition of adhesion molecules and subsequent mono-
cytic adherence by moderating the reduction in eNOS
expression caused by oxLDL.
The concentrations of ellagic acid (5-20 M) used in
our experiments were similar to those that have been re-
ported to suppress aortic smooth muscle cell proliferation,
anti-inflammation in human aorta endothelial cells, and G1
arrest and apoptosis in cervical carcinoma (CaSki) cells.15,16,37
In animals, the peak plasma concentration after oral admin-
istration of an ellagic acid-phospholipid complex (equiva-
lent to 80 mg/kg) was 2 M. That concentration of ellagic
acid was sufficient to restore the levels of antioxidant en-
zymes that had been impaired by administration of carbon
tetrachloride.38 The typical dietary intake of ellagic acid in
humans, based on the consumption of 200 g of strawber-
ries or blackberries, is approximately 40 to 80mg/d.39 The
dose of ellagic acid used in the present study is equivalent to
the dietary intake of approximately 200 g of berries. In
humans, ellagic acid was detected in plasma at a maximum
concentration of 31.9 ng/mL after 1 hour post-ingestion
of 180 mL of pomegranate juice containing 25 mg of
ellagic acid and 318 mg of ellagitannins.40 Thus, the con-
centrations of ellagic acid used in the present study are
comparable to those achievable physiologically. It is, how-
ever, unclear whether prolonged use of ellagic acid would
lead to chronic accumulation in different tissues.
CONCLUSIONS
Ellagic acid possesses antioxidative, anticarcinogenic,
and anti-inflammatory properties, making it a potential
candidate agent for the prevention and treatment of several
types of cancers and cardiovascular diseases. More research
into the molecular mechanisms by which ellagic acid exerts
its effects is needed. Our findings provide pharmacological
evidence that ellagic acid helps prevent against the devel-
opment of atherosclerosis.
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According to the findings of the National Vital Statistics
Report and the Morbidity and Mortality Weekly report of the
Centers for Disease Control and Prevention (CDC), cardiovascu-
lar disease continues to rank high among the leading causes of
morbidity and mortality in adults in the United States. It is well
known that most Americans are overfed and under-exercised, but
what is much less well-known is how bad nutrition is causing an
alarming increase in the frequency of obesity, heart disease, stroke,
cancer, diabetes, and even dementia. Several epidemiological stud-
ies suggest that dietary patterns characterized by relatively high
intake of fruits and vegetables are significantly associated with
reduced risks of coronary heart disease and stroke. These foods
have phytochemicals including carotenoids, and polyphenols like
flavonoids, resveratrol and ellagitannins, iosthiocyanates and orga-
nosulfur compounds, each of which has been shown to be associ-
ated with lower risk of cardiovascular disease. Phytochemicals are
potent antioxidants and anti-inflammatory agents, thereby coun-
teracting oxidative damage and inflammation, which underlie the
pathogenesis of cardiovascular disease. The authors present more
data showing the importance of a diet high in polyphenols such as
ellagic acid (ellagitannins). The authors show for the first time that
pretreatment of endothelial cells with ellagic acid protected againstmediated signaling pathway. The proatherosclerotic role of LOX-1
was made clear by Mehta and Sawamura when they reported that a
LOX-1 knockout mouse model had reduced formation of athero-
sclerotic lesions in a proatherogenic genetic background under a
high-cholesterol diet. Proatherosclerotic and pro-oxidative signal-
ing and inflammatory response were measured as vascular NF-B,
CD68 expression, and p38 MAPK activation. Endothelial cell
function was preserved, therefore providing proof of concept that
LOX-1 was proatherosclerotic. There is evidence of LOX-1-
increased expression in atherosclerotic plaques from human sam-
ples. There are also interesting studies showing that patients re-
ceiving ACE inhibitors and statins (Endothelial Protection, AT1
blockage and Cholesterol-Dependent Oxidative Stress [EPAS]
trial) independently and in combination had improved endothelial
expression quotient of anti- and proatherosclerotic genes such as
LOX-1. Further of interest is a small randomized controlled trial
involving 19 patients with carotid artery stenosis found that pome-
granate juice, high in ellagic acid, appeared to rescue blood pres-
sure and carotid wall thickness. Inhibition of LOX-1 might be an
interesting and novel therapeutic strategy in the treatment of
atherosclerosis. One might even postulate from the authors’ work
that a diet high in polyphenols, especially ellagic acid, could lead to
prevention of atherosclerotic disease or even regression.
